An evaluation of short-acting β2-agonist prescriptions and associated clinical outcomes in asthma management in Indonesia – the SABINA Indonesia study
DOI:
https://doi.org/10.36497/jri.v42i2.295Keywords:
asthma, SABA, over-prescription, exacerbationAbstract
Background: Asthma is a chronic inflammatory disease, therefore inhaled corticosteroid (ICS) should be as the cornerstone of asthma treatment. However patients tend to rely on short-acting β2-agonist (SABA) due to immediate symptom relief and underuse ICS, thereby undertreating the underlying inflammation. As part of the multi-country SABA use IN Asthma (SABINA) III study, we aimed to describe SABA prescription patterns and asthma-related clinical outcome in Indonesia.
Methods: Cross-sectional study in asthma patients (> 12 years old) during August 2019 – January 2020. Disease characteristic, prescribed asthma treatment in the 12 months before the study visit, and clinical outcomes, were recorded during a single visit and entered into an electronic case report form.
Results: Of 219 patients recruited, the mean number of SABA canisters prescribed was 4 canisters per year. SABA over-prescription (≥ 3 canisters/year) seen in 37% patients, and was greater in moderate-to-severe vs mild asthma (40% vs 17.9%). 47.5% of patients had at least 1 severe exacerbation; and 7.3% of patients had ≥3 severe exacerbations, in the past 12 months. Almost half of the patients (40.2%) were prescribed oral corticosteroids (OCS). Overall, the well-, partly, and uncontrolled patients were 41.6%, 37.4%, and 21%, respectively.
Conclusion: SABA over-prescription occurs in approximately one third of asthma patients, especially among moderate-to-severe patients and almost half of asthma patients experienced at least 1 severe exacerbation in the previous year. This highlights a public health concern and the need to improve asthma care by aligning with global recommendations including reducing SABA over-reliance in IndonesiaDownloads
References
Asthma GIf. Pocket Guide for Asthma Management and Prevention 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf.
Stallberg B, Lisspers K, Hasselgren M, Janson C, Johansson G, Svardsudd K. Asthma control in primary care in Sweden: a comparison between 2001 and 2005. Primary care respiratory journal : journal of the General Practice Airways Group. 2009;18(4):279-86.
Network GA. The Global Asthma Report 20182018. Available from: www.globalasthmanetwork.org.
Barnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respiratory care. 2015;60(3):455-68.
RI KK, editor Hasil Utama Riskesdas 20182018.
Asthma GIf. Global Strategy for Asthma Management and Prevention 2017. Available from: http://www.ginasthma.org/.
Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, et al. SABINA: An Overview of Short-Acting beta2-Agonist Use in Asthma in European Countries. Advances in therapy. 2020;37(3):1124-35.
Bloom CI, Cabrera C, Arnetorp S, Coulton K, Nan C, van der Valk RJP, et al. Asthma-Related Health Outcomes Associated with Short-Acting beta2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Advances in therapy. 2020;37(10):4190-208.
Pearce N, Hensley MJ. Epidemiologic studies of beta agonists and asthma deaths. Epidemiologic reviews. 1998;20(2):173-86.
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. The New England journal of medicine. 2018;378(20):1865-76.
Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. The New England journal of medicine. 2018;378(20):1877-87.
Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM. Has Asthma Medication Use Caught Up With the Evidence?: A 12-Year Population-Based Study of Trends. Chest. 2017;151(3):612-8.
Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. The European respiratory journal. 2019;53(6).
Cabrera CS, Nan C, Lindarck N, Beekman M, Arnetorp S, van der Valk RJP. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting beta2-agonist use in asthma. The European respiratory journal. 2020;55(2).
Worth H, Criee CP, Vogelmeier CF, Kardos P, Becker EM, Kostev K, et al. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respiratory research. 2021;22(1):108.
Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. The European respiratory journal. 2020;55(4).
Wang CY, Lai CC, Wang YH, Wang HC. The prevalence and outcome of short-acting beta2-agonists overuse in asthma patients in Taiwan. NPJ primary care respiratory medicine. 2021;31(1):19.
Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. The European respiratory journal. 2021.
Asthma GIf. Global Strategy for Asthma Management and Prevention 2021. Available from: www.ginasthma.org.
Cusack RP, Satia I, O'Byrne PM. Asthma maintenance and reliever therapy: Should this be the standard of care? Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2020;125(2):150-5.
Azzi EA, Kritikos V, Peters MJ, Price DB, Srour P, Cvetkovski B, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ open. 2019;9(8):e028995.
Gold LS, Thompson P, Salvi S, Faruqi RA, Sullivan SD. Level of asthma control and health care utilization in Asia-Pacific countries. Respiratory medicine. 2014;108(2):271-7.
Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC pulmonary medicine. 2017;17(1):74.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
